Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
VYGR on Nasdaq
Shares outstanding
55,482,166
Price per share
$3.93
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
30,211,020
Total reported value
$141,111,218
% of total 13F portfolios
0%
Share change
-3,000,957
Value change
-$12,466,233
Number of holders
114
Price from insider filings
$3.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 7.6% -23% $19,614,000 -$5,772,120 4,200,000 -23% Armistice Capital, LLC 30 Sep 2025
EcoR1 Capital, LLC 6.8% $18,696,980 4,003,636 EcoR1 Capital, LLC 30 Sep 2025
BlackRock, Inc. 6.4% $10,893,894 3,525,532 BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 114 institutional investors reported holding 30,211,020 shares of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR). This represents 54% of the company’s total 55,482,166 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 10% 5,607,271 -2.2% 0% $26,185,956
ARMISTICE CAPITAL, LLC 7.6% 4,200,000 -12% 0.62% $19,614,000
VANGUARD GROUP INC 5.9% 3,250,066 +1.3% 0% $15,177,809
MILLENNIUM MANAGEMENT LLC 4.1% 2,292,703 +154% 0.01% $10,706,923
Vestal Point Capital, LP 2.7% 1,475,000 0% 0.31% $6,888,250
DIMENSIONAL FUND ADVISORS LP 2.3% 1,283,156 -9.7% 0% $5,992,508
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,148,612 +2.8% 0% $5,364,995
Erste Asset Management GmbH 2% 1,116,793 0% 0.05% $5,260,095
STATE STREET CORP 1.7% 925,358 +3.5% 0% $4,321,422
EcoR1 Capital, LLC 1.2% 670,303 -83% 0.15% $3,130,315
MORGAN STANLEY 1.1% 599,688 +6.4% 0% $2,800,543
PRICE T ROWE ASSOCIATES INC /MD/ 1% 581,699 -4.8% 0% $2,718,000
UBS Group AG 0.85% 473,100 +3.9% 0% $2,209,378
BANK OF AMERICA CORP /DE/ 0.77% 427,430 -26% 0% $1,996,099
CITADEL ADVISORS LLC 0.72% 398,226 +105% 0% $1,859,715
NORTHERN TRUST CORP 0.71% 394,751 -2.4% 0% $1,843,488
Fiduciary Trust Co 0.6% 334,397 +29% 0.02% $1,561,634
GOLDMAN SACHS GROUP INC 0.54% 297,573 +5.9% 0% $1,389,666
RENAISSANCE TECHNOLOGIES LLC 0.47% 262,450 -33% 0% $1,225,642
ROYAL BANK OF CANADA 0.44% 242,672 -16% 0% $1,133,000
JPMORGAN CHASE & CO 0.39% 217,411 -1.3% 0% $1,015,310
SPHERA FUNDS MANAGEMENT LTD. 0.36% 199,761 0.22% $932,884
Bank of New York Mellon Corp 0.35% 193,415 +2.5% 0% $903,248
GSA CAPITAL PARTNERS LLP 0.33% 184,203 -18% 0.07% $860,000
AQR CAPITAL MANAGEMENT LLC 0.32% 176,216 -38% 0% $822,928

Institutional Holders of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 18,315 $71,979 +$68,386 $3.93 4
2025 Q3 30,211,020 $141,111,218 -$12,466,233 $4.67 114
2025 Q2 33,174,848 $103,119,298 -$5,022,785 $3.11 108
2025 Q1 34,693,910 $117,319,170 -$2,379,831 $3.38 114
2024 Q4 34,575,480 $195,985,371 -$3,239,012 $5.67 130
2024 Q3 35,034,671 $205,127,664 -$20,241,646 $5.85 126
2024 Q2 38,132,801 $301,619,976 +$18,919,368 $7.91 126
2024 Q1 35,559,200 $331,104,876 +$80,222,771 $9.31 132
2023 Q4 1,071,646 $9,114,585 $8.47 2
2023 Q3 26,192,943 $202,992,457 +$537,249 $7.75 110
2023 Q2 25,625,855 $293,412,781 +$48,054,170 $11.45 104
2023 Q1 22,655,946 $174,668,757 -$217,880 $7.71 80
2022 Q4 22,745,690 $138,712,206 -$503,548 $6.10 66
2022 Q3 22,650,034 $134,095,666 -$773,505 $5.92 65
2022 Q2 22,785,831 $134,689,837 +$8,689,014 $5.91 71
2022 Q1 21,209,102 $161,609,288 +$28,891,132 $7.62 65
2021 Q4 17,513,390 $47,461,458 -$8,943,576 $2.71 46
2021 Q3 21,279,959 $56,077,444 -$4,248,045 $2.63 63
2021 Q2 21,935,865 $90,592,347 -$15,594,745 $4.13 69
2021 Q1 25,613,791 $120,638,752 -$5,402,575 $4.71 89
2020 Q4 27,153,928 $194,151,698 -$5,004,684 $7.15 91
2020 Q3 27,728,762 $296,010,349 -$21,154,618 $10.67 105
2020 Q2 29,235,893 $368,944,915 -$4,466,264 $12.62 103
2020 Q1 29,014,657 $265,408,612 -$11,901,664 $9.15 111
2019 Q4 30,363,736 $423,143,577 -$7,294,591 $13.95 130
2019 Q3 30,362,562 $522,533,433 +$3,395,721 $17.21 124
2019 Q2 28,989,476 $788,286,007 +$141,649,313 $27.22 122
2019 Q1 27,155,626 $519,774,380 +$3,584,614 $19.14 106
2018 Q4 27,783,714 $261,157,459 -$17,030,889 $9.40 111
2018 Q3 28,911,983 $547,047,014 -$4,055,482 $18.92 115
2018 Q2 29,099,816 $568,637,489 +$41,405,160 $19.54 124
2018 Q1 27,065,518 $508,505,214 +$36,985,585 $18.79 106
2017 Q4 25,186,221 $418,084,441 +$68,372,247 $16.60 97
2017 Q3 11,312,957 $232,911,475 +$24,131,408 $20.59 74
2017 Q2 10,948,552 $98,099,874 -$1,702,263 $8.96 51
2017 Q1 11,060,319 $146,436,026 +$8,714,463 $13.24 45
2016 Q4 10,953,507 $139,539,414 +$4,079,352 $12.74 54
2016 Q3 10,637,831 $127,760,820 +$781,538 $12.01 50
2016 Q2 10,598,201 $116,470,479 +$5,974,386 $10.99 48
2016 Q1 10,015,808 $86,972,821 -$3,381,113 $8.73 41
2015 Q4 10,401,774 $225,107,498 +$219,920,201 $21.90 34